Literature DB >> 18316605

Clonal selection in malignant transformation of human fibroblasts transduced with defined cellular oncogenes.

Alka M Mahale1, Zahid A T Khan, Makoto Igarashi, Gouri J Nanjangud, Rui Fang Qiao, Shen Yao, Sam W Lee, Stuart A Aaronson.   

Abstract

Recent evidence has implied that disruption of a limited number of defined cellular pathways is necessary and sufficient for neoplastic conversion of a variety of normal human cell types in tissue culture. We show instead that malignancy in such models results from an iterative process of clonal selection in vitro and/or in vivo. Normal human fibroblasts underwent malignant transformation after transduction with telomerase, cyclin-dependent kinase 4, dominant-negative p53, and activated Ras or MEK. Furthermore, culture conditions favoring overgrowth resulted in clonal selection, which with added Ras or MEK oncogenes led to the emergence of tumorigenic clones. Such tumors showed variable degrees of malignancy with some even exhibiting metastasis. SV40 small t antigen (ST) has been reported to be necessary and sufficient to convert human fibroblasts with these pathway aberrations to a polyclonal tumor. However, we observed that clonal tumors emerged even with ST addition. Genomic instability was markedly increased by p53 and Rb pathway abrogation. Under the same conditions, fibroblasts with these alterations failed to induce tumors, implying that genomic instability may be necessary but not sufficient for malignant transformation. These findings indicate that the minimum number of events required for malignant transformation of human fibroblasts is greater than has been enumerated by such oncogene addition strategies and support a stochastic cancer progression model initiated by four defined cellular alterations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316605     DOI: 10.1158/0008-5472.CAN-07-3021

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Role of progerin-induced telomere dysfunction in HGPS premature cellular senescence.

Authors:  Erica K Benson; Sam W Lee; Stuart A Aaronson
Journal:  J Cell Sci       Date:  2010-07-06       Impact factor: 5.285

2.  Biosafety assessment of site-directed transgene integration in human umbilical cord-lining cells.

Authors:  Jaichandran Sivalingam; Shruti Krishnan; Wai Har Ng; Sze Sing Lee; Toan Thang Phan; Oi Lian Kon
Journal:  Mol Ther       Date:  2010-04-27       Impact factor: 11.454

3.  Protection of cells in physiological oxygen tensions against DNA damage-induced apoptosis.

Authors:  Samantha Carrera; Petra J de Verdier; Zahid Khan; Bo Zhao; Alka Mahale; Karen J Bowman; Muri Zainol; George D D Jones; Sam W Lee; Stuart A Aaronson; Salvador Macip
Journal:  J Biol Chem       Date:  2010-03-12       Impact factor: 5.157

Review 4.  Do mutator mutations fuel tumorigenesis?

Authors:  Edward J Fox; Marc J Prindle; Lawrence A Loeb
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

Review 5.  Mutational heterogeneity in human cancers: origin and consequences.

Authors:  Jesse J Salk; Edward J Fox; Lawrence A Loeb
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

6.  Transcriptional Dynamics of Immortalized Human Mesenchymal Stem Cells during Transformation.

Authors:  Masao Takeuchi; Atsunori Higashino; Kikuko Takeuchi; Yutaro Hori; Kazuko Koshiba-Takeuchi; Hatsune Makino; Yoko Monobe; Marina Kishida; Jun Adachi; Jun Takeuchi; Takeshi Tomonaga; Akihiro Umezawa; Yosuke Kameoka; Ken-Ichi Akagi
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

7.  Immortality of cancers: a consequence of inherent karyotypic variations and selections for autonomy.

Authors:  Peter Duesberg; Amanda McCormack
Journal:  Cell Cycle       Date:  2013-02-06       Impact factor: 4.534

8.  Karyotype alteration generates the neoplastic phenotypes of SV40-infected human and rodent cells.

Authors:  Mathew Bloomfield; Peter Duesberg
Journal:  Mol Cytogenet       Date:  2015-10-22       Impact factor: 2.009

9.  Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations.

Authors:  Albino Troilo; Erica K Benson; Davide Esposito; Rachel-Ann A Garibsingh; E Premkumar Reddy; Sathish Kumar Mungamuri; Stuart A Aaronson
Journal:  Oncotarget       Date:  2016-05-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.